Literature DB >> 8387893

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.

K Pfeffer1, T Matsuyama, T M Kündig, A Wakeham, K Kishihara, A Shahinian, K Wiegmann, P S Ohashi, M Krönke, T W Mak.   

Abstract

The multiple biological activities of tumor necrosis factor (TNF) are mediated by two distinct cell surface receptors of 55 kd (TNFRp55) and 75 kd (TNFRp75). Using gene targeting, we generated a TNFRp55-deficient mouse strain. Cells from TNFRp55-/-mutant mice lack expression of TNFRp55 but display normal numbers of high affinity TNFRp75 molecules. Thymocyte development and lymphocyte populations are unaltered, and clonal deletion of potentially self-reactive T cells is not impaired. However, TNF signaling is largely abolished, as judged by the failure of TNF to induce NF-kappa B in T lymphocytes from TNFRp55-deficient mice. The loss of TNFRp55 function renders mice resistant to lethal dosages of either lipopolysaccharides or S. aureus enterotoxin B. In contrast, TNFRp55-deficient mice are severely impaired to clear L. monocytogenes and readily succumb to infection. Thus, the 55 kd TNFR plays a decisive role in the host's defense against microorganisms and their pathogenic factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387893     DOI: 10.1016/0092-8674(93)90134-c

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  451 in total

1.  Assessing vascular permeability during experimental cerebral malaria by a radiolabeled monoclonal antibody technique.

Authors:  H C van der Heyde; P Bauer; G Sun; W L Chang; L Yin; J Fuseler; D N Granger
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 2.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

Review 3.  Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis.

Authors:  M W Cunningham
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Critical role for perforin-, Fas/FasL-, and TNFR1-mediated cytotoxic pathways in down-regulation of antigen-specific T cells during persistent viral infection.

Authors:  Shenghua Zhou; Rong Ou; Lei Huang; Demetrius Moskophidis
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 5.  TNF ligands and receptors--a matter of life and death.

Authors:  David J MacEwan
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

6.  Characterization of tumor necrosis factor-deficient mice.

Authors:  M W Marino; A Dunn; D Grail; M Inglese; Y Noguchi; E Richards; A Jungbluth; H Wada; M Moore; B Williamson; S Basu; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

7.  Deficiency in tumor necrosis factor alpha activity does not impair early protective Th1 responses against blood-stage malaria.

Authors:  H Sam; Z Su; M M Stevenson
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

8.  Role of NFkappaB in the mortality of sepsis.

Authors:  H Böhrer; F Qiu; T Zimmermann; Y Zhang; T Jllmer; D Männel; B W Böttiger; D M Stern; R Waldherr; H D Saeger; R Ziegler; A Bierhaus; E Martin; P P Nawroth
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

9.  Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Simona Stäger; Clare E Alexander; Amanda C Stanley; Paul M Kaye
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1beta (IL-1beta) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism.

Authors:  T G Gleason; C W Houlgrave; A K May; T D Crabtree; R G Sawyer; W Denham; J G Norman; T L Pruett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.